Tiziana Life Sciences Completes Enrollment for Key Phase 2a MS Trial; Topline Data Expected Late Q3 2026
TLSA sits 47% above its 52-week low of $1.14.
Summary
Tiziana Life Sciences has completed patient enrollment for its Phase 2a clinical trial of intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis, with topline data anticipated in late Q3 2026. This marks a significant step forward for its lead candidate.
Key Events · Product Development and Regulatory · TLSA
-
Phase 2a MS Trial Enrollment Completed
Tiziana Life Sciences has fully enrolled its randomized, double-blind, placebo-controlled Phase 2a clinical trial (INFORM-MS) for intranasal foralumab in non-active Secondary Progressive Multiple Sclerosis (na-SPMS).
-
Topline Data Expected Late Q3 2026
Topline results from the 48-patient study are anticipated in late Q3 2026 and will also be presented at the 10th joint ACTRIMS and ECTRIMS meeting in October 2026.
-
First Placebo-Controlled Study
This trial is the first placebo-controlled study of intranasal foralumab, a critical step for robust data generation for the novel anti-CD3 monoclonal antibody.
-
Addresses 'Going Concern' Context
This clinical progress is particularly important following the company's recent 'going concern' warning, demonstrating advancement of its lead asset.
Analysis · TLSA · Life Sciences
This announcement confirms the successful completion of patient enrollment for Tiziana's pivotal Phase 2a clinical trial of intranasal foralumab in non-active Secondary Progressive Multiple Sclerosis. This milestone de-risks trial execution and sets a clear timeline for topline data in late Q3 2026, which is critical for the company, especially given its recent 'going concern' disclosure. The trial is the first placebo-controlled study for this novel therapy, making its results highly anticipated for the company's future.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLSA was trading at $1.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $199.1M. The 52-week trading range was $1.14 to $2.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.